Abstract
Chronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. It has a prevalence of 3.5 cases / 10,000 inhabitants and an annual incidence of 5 new cases / 100,000 inhabitants. The incidence increases to> 30 cases / 100,000 / year in patients> 70 years. It affects more frequently men than women (2: 1)
Keywords
Ibrutinib; Monotherapy; Chronic lymphocytic leukemia
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Ibrutinib per al tractament de la leucèmia limfocítica crònica. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4131This item appears in following collections
The following license files are associated with this item: